Brean Capital analyst Jonathan Aschoff came out today with a research note on Nektar Therapeutics (NASDAQ:NKTR), reducing the price target to $17 (from $20) and …
In a research report released on Monday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Inovio Pharmaceuticals Inc (NASDAQ:INO) with a …
Brean Capital’s healthcare analyst Jonathan Aschoff weighed in today with a few insights on Neuralstem, Inc. (NYSE MKT:CUR), after the company released its fourth-quarter results and …
In a research note published Thursday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Neuralstem, Inc. (NYSE MKT:CUR) with an $8 price target, after …
Brean Capital analyst Jonathan Aschoff weighed in today with a few insights on Cytosorbents Corp (NASDAQ:CTSO), after hosting management meetings with the company yesterday. The analyst rates …
In a research report released this morning, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Neuralstem, Inc. (NYSE MKT:CUR) with an $8.
In a research note released today, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) with an $11 price target, after …
In a research report published Friday, Brean Capital analyst Jonathan Aschoff maintained a Sell rating on Rockwell Medical Inc (NASDAQ:RMTI) with a $4.00 price target, …
In a research report published Thursday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Medivation Inc (NASDAQ:MDVN) and raised the price target to $125 (from $118), …
In a research report issued today, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on WaferGen Bio-systems, Inc. (NASDAQ:WGBS) with a price target of …
